title: Emerging drugs for adrenocortical carcinoma.
abstract: BACKGROUND
  Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease.
  
  
  OBJECTIVE
  this paper will review the existing treatment strategies and new perspectives in the management of ACC patients.
  
  
  CONCLUSIONS
  An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.
authors.affiliation: Department of Clinical and Biological Science, Oncologia Medica, University of Turin, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy. alfredo.berruti@gmail.com
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
authors.forename: Anna
authors.initials: A
authors.lastname: Ferrero
authors.forename: Paola
authors.initials: P
authors.lastname: Sperone
authors.forename: Fulvia
authors.initials: F
authors.lastname: Daffara
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Reimondo
authors.forename: Mauro
authors.initials: M
authors.lastname: Papotti
authors.forename: Luigi
authors.initials: L
authors.lastname: Dogliotti
authors.forename: Alberto
authors.initials: A
authors.lastname: Angeli
authors.forename: Massimo
authors.initials: M
authors.lastname: Terzolo